Your location:Home > News Center> Company News
News Center

Lisen Announces a New Innovative and Highly Accurate Epigenetic Solution for Early Cancer Detection

Lisen's methodology paper which innovatively applied visualized epigenetic imprinting biomarkers in the early detection of various cancers has been published in the open access journal Clinical Epigenetics on May 24. Lisen developed and patented the QCIGISH (Quantitative Chromogenic Imprinted Gene In-Situ Hybridization) technology - a novel approach in identifying, visualizing, and quantifying the biallelic and multiallelic expressions of an imprinted gene panel associated with cancer status. In a 1013-case clinical study involving ten different cancer types including bladder, breast, colorectal, esophageal, gastric, lung, pancreatic, prostate, skin and thyroid cancers, QCIGISH achieved 94% overall sensitivity and 92% overall specificity. The paper was a collaborative work between Lisen and researchers from various medical universities and centers including Ohio State University, Johns Hopkins University, University of Texas, Fudan University, Tongji University, Chinese Navy Medical University, Jiangsu Jiangyuan Hospital, Chinese Academy of Medical Science. The paper's primary author was Dr. Rulong Shen, a pathologist of Ohio State University Wexner Medical Center. Dr. Chunxue Bai, chief physician and professor of Zhongshan Hospital of Fudan University, and Dr. Ning Zhou, Lisen's CEO and co-founder, were the corresponding authors. The official press release made by Lisen was immediately picked up by various media including yahoo and digital journal.